Defective fibrinolytic states as triggers of myocardial infarction: The cardiologist's view

Italian Heart Journal

Volumn 2, Issue 9, 2001, Pages 646-651

  Huber, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fibrinolytic system; Myocardial infarction; Plasminogen activator inhibitor type 1; Tissue type plasminogen activator

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; DOXAZOSIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; INSULIN; METFORMIN; NICOTINIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOLOGY; CONTROLLED STUDY; DRUG MECHANISM; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEREDITY; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MEDICAL SPECIALIST; PATHOGENESIS; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; THROMBOSIS;

BLOOD COAGULATION DISORDERS; FIBRINOLYSIS; HUMANS; MYOCARDIAL INFARCTION;

EID: 0034760268     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
2. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
3. Hemostasis risk markers, inflammatory and endothelial reactions in angina pectoris
4. Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events
5. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina
6. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
7. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women
8. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
9. Plasminogen activator inhibitor in blood of patients with coronary artery disease
10. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction
11. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
12. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
13. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis
14. Plasminogen activator inhibitor-1 and atherothrombosis
15. The relationship between impaired fibrinolysis and coronary heart disease
16. Association of fibrinolytic parameters with early atherosclerosis
17. Tissue-type plasminogen activator and type-1 plasminogen activator inhibitor in patients with coronary artery disease: Relations to clinical variables and cardiovascular risk factors
18. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischemic heart disease
19. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
20. PAI-1 gene polymorphism in patients with coronary artery disease and malignant ventricular arrhythmias
21. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnnish men who died suddenly
22. Circadian variation in the frequency of onset of acute myocardial infarction
23. Circadian variation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
24. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)
25. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct-related artery after thrombolytic therapy in acute myocardial infarction
26. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction
27. The status of PAI-1 as a risk factor for arterial and thrombotic disease
28. Lysis of platelet-rich thrombi: The role of PAI-1
29. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor?
30. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator
31. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets
32. Thrombolytic therapy in acute myocardial infarction
33. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction
34. Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation
35. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration
36. Plasma levels of plasminogen activator inhibitor type 1, beta-thrombomodulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase
37. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat
38. Rebound increase of plasminogen activator inhibitor type 1 after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used
39. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart study
40. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo
41. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation: Effect of interleukin
42. On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction
43. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
44. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: A case-control study
45. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
46. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischemic heart disease in the Caerphilly study
47. Fibrinolytic activation markers predict myocardial infarction in the elderly
48. Thrombogenic factors and recurrent coronary events
49. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis
50. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity
51. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
52. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants
53. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene
54. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentration: A family study with part of the Stanislas cohort
55. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. A potential factor predisposing to thrombosis and its persistence
56. Insulin resistance and changes in haemostatic variables
57. A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100
58. Reduced fibrinolytic response in obese children: Association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1)
59. Production of plasminogen activator inhibitor-1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
60. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
61. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals
62. The adipocyte and hemostatic balance in obesity: Studies of PAI-1
63. Stimulation of tissue-type plasminogen activator in vivo by infusion of bradykinin
64. Angiotensin II increases plasminogen activator inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
65. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells
66. Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells
67. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease
68. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells
69. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
70. Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity
71. Dietary regulation of fibrinolytic factors
72. Effects of exercise training on plasminogen activator inhibitor activity
73. Fibrinolytic and hemostatic parameter response after resistance exercise
74. The insulin resistance syndrome in smokers is related to smoking habits
75. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study
76. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease
77. The activation of plasminogen activator inhibitor-1 expression by IL-1β is attenuated by estrogen in hepatoblastoma hepG2 cells expressing estrogen receptors
78. Relationship between smoking and fibrinolytic system with special reference to tPA and PA inhibitor
79. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking
80. Ethyl alcohol enhances plasminogen activator secretion by endothelial cells
81. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke
82. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control
83. Metformin decreases the high plasminogen activator inhibitor capacity plasma insulin and triglyceride levels in non diabetic obese subjects
84. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients
85. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors
86. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol
87. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters
88. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction
89. Direct effects of gemfibrozil on the fibrinolytic system
90. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy
91. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis
92. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
93. HMG-CoA reductase inhibitors affect the fibrinolytic system of human smooth muscle cells in vitro
94. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells
95. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults
96. Amelioration of the inhibition of fibrinolysis in the elderly, obese subjects by moderate energy intake restriction
97. PAI-1, obesity, insulin resistance and risk of cardiovascular events
98. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss
99. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction
100. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
101. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
102. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction
103. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
104. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin-converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure
105. Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
106. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension
107. A faster-acting and more potent form of tissue plasminogen activator
108. Pathologic basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue-type plasminogen activator in coronary thrombosis
109. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator
110. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators